Researchers report the first structural confirmation that endogenous — or self-made — molecules can set off innate immunity in mammals via a pair of immune cell proteins called the TLR4-MD-2 receptor complex. The work has wide-ranging implications for finding ways to treat and possibly prevent autoimmune diseases such as multiple sclerosis and antiphospholipid syndrome.